74150-27-9 Usage
Description
Pimobendan, also known as Acardl, is a novel cardiotonic vasodilator that belongs to the pyridazinone and benzimidazoles class of compounds. It functions as a cardiotonic drug, a vasodilator agent, and an inhibitor of phosphoric diester hydrolase (EC 3.1.4.). Pimobendan is characterized by its white solid chemical properties and was introduced in Japan for the treatment of acute and mild to moderate chronic heart failure.
Uses
1. Used in Cardiology:
Pimobendan is used as a cardiotonic agent for the treatment of various cardiac diseases, including congestive heart failure (CHF). It acts by inhibiting phosphodiesterase III and potassium channels, enhancing the sensitization of myocardial contractile regulatory protein to calcium ions, and contributing to its inotropic activity. This improves cardiac index, stroke volume index, pulmonary wedge pressure, and systemic and pulmonary vascular resistance in patients with severe congestive heart failure.
2. Used in Pharmaceutical Industry:
Pimobendan is used as a selective inhibitor of PDE3 with an IC50 of 0.32 μM. Its dual properties as an inotropic and vasodilatory agent make it a valuable drug for the development of treatments for heart failure and other cardiac conditions.
3. Used in Combination Therapy:
Pimobendan is used in combination with an ACE inhibitor, such as enalapril, to provide superior treatment outcomes for heart failure patients. Studies suggest that this combination may be more effective than monotherapy.
Originator
Boehringer
lngelhelm (Germany)
Biological Activity
Pimobendan is an inhibitor of phosphodiesterase 3 (PDE3; IC50 = 0.32 μM for guinea pig cardiac enzyme) that is selective for PDE3 over PDE1, PDE2, and PDE4 (IC50s = >30 μM). It is also a calcium sensitizer, decreasing the concentration of calcium required for half-maximal contractile force in isolated, skinned porcine ventricular fibers. Pimobendan increases the force of contraction in electrically-stimulated isolated guinea pig papillary muscles with an EC50 value of 6 μM, indicating positive inotropic effects. It increases survival time in dogs with congestive heart failure due to myxomatous mitral valve disease when administered in combination with angiotensin-converting enzyme inhibitors and furosemide . Formulations containing pimobendan have been used in the treatment of heart failure in dogs.
Biochem/physiol Actions
Pimobendan is an inotropic agent with a dual mechanism of action: it increases myocardial contractility by increasing calcium sensitization to troponin C and it promotes vasodilation by inhibiting phosphodiesterase III (PDE3). Pimobendan has been studied for treating heart failure and cardiomyopathy, primarily for veterinary uses.
Veterinary Drugs and Treatments
Pimobendan is used to treat dogs with congestive heart failure secondary
to dilated cardiomyopathy or chronic mitral valve insufficiency
(CMVI).
Check Digit Verification of cas no
The CAS Registry Mumber 74150-27-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,4,1,5 and 0 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 74150-27:
(7*7)+(6*4)+(5*1)+(4*5)+(3*0)+(2*2)+(1*7)=109
109 % 10 = 9
So 74150-27-9 is a valid CAS Registry Number.
InChI:InChI=1/C19H18N4O2/c1-11-9-16(22-23-19(11)24)13-5-8-15-17(10-13)21-18(20-15)12-3-6-14(25-2)7-4-12/h3-8,10-11H,9H2,1-2H3,(H,20,21)(H,23,24)/t11-/m1/s1
74150-27-9Relevant articles and documents
Preparation method of pimobendan
-
Paragraph 0015; 0022-0023, (2021/10/11)
The invention relates to a novel preparation process of pimobendan. Specifically, a Suzuki coupling reaction is carried out on a compound shown as a formula I (6-(2-bromo-1H-benzo[d]imidazol-6-yl)-5-methyl-4, 5-dihydropyridazin-3(2H)-one) and a compound shown as a formula II (p-methoxyphenylboronic acid or p-methoxyphenylboronic acid pinacol ester) under the action of a Pd catalyst, so that the preparation of the pimobendan is realized.
Novel method for preparing pimobendan from by-product for synthesizing pimobendan
-
Paragraph 0009; 0010; 0011, (2019/01/08)
The invention discloses a novel method for preparing pimobendan from a by-product for synthesizing the pimobendan. The method comprises the following steps that the by-product (the chemical name is (5RS)-6-[1-(4-methoxybenzyl)-2-(4-methoxyphenyl)-1H-benzimidazole-6-yl]-5-methyl-4,5-dihydro-3(2H)-pyridazinone) obtained in the pimobendan synthesizing process is dissolved into a mixed solvent and reacts with ceric ammonium nitrate (CAN) at 20-25 DEG C for 2-3 hours so as to obtain a pimobendan crude product; and the obtained pimobendan crude product is heated and refluxed in an organic solvent, and cooling, filtering and drying are carried out so as to obtain the pimobendan. According to the method, the unwanted by-product is converted into a required pimobendan product, waste is turned intowealth, and therefore the production cost is greatly lowered.
CRYSTALLINE PIMOBENDAN, PROCESS FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION AND USE
-
, (2011/07/06)
The invention relates to a pharmaceutical composition containing pimobendan as an active ingredient. The invention also relates to a crystalline form of pimobendan, as well as to a combination of said crystalline form with at least one other therapeutically active ingredient. Moreover, the invention relates to uses of said crystalline form, as well as to a pharmaceutical composition containing it. Finally, the invention relates to a process for preparing a crystalline form of pimobendan.
